EUVIMEDEUVIMED entdecken
Open Access

T-cell and autoantibody profiling for primary immune regulatory disorders

Emily M Harris, Sarah Chamseddine, Anne Chu, Leetah Senkpeil, Matthew Nikiciuk, Aleksandra Bourdine, Logan Magin, Amer Al-Musa, Brian Woods, Elif Ozdogan, Sarife Saker, David P Hoytema van Konijnenburg und 16 weitere

Journal of Allergy and Clinical Immunology · 2025

DOI: 10.1016/j.jaci.2025.06.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025. Verfasst von Emily M Harris und 27 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Mass. Hauptthemen laut MEDLINE: Autoantibodies, Autoimmune Diseases, T Follicular Helper Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Limited clinical tools exist for characterizing primary immune regulatory disorders (PIRD). Increased CD4+CXCR5+PD1+ circulating T follicular helper (cTfh) cell percentages have been identified as a marker of active disease in some, but not all, autoimmune disorders. OBJECTIVE: We sought to develop a diagnostic approach that combines measurements of cellular and serologic autoimmunity. METHODS: We recruited 74 controls and 101 pediatric patients with PIRD with autoimmunity. Flow cytometry was used to measure CD4+CXCR5+ T cells expressing the chemokine receptors CXCR3 and/or CCR6. IgG and IgA autoantibodies were quantified in 56 patients and 20 controls using a microarray of 1616 full-length, conformationally intact protein antigens. The cTfh cell percentages exceeding 12% of CD4+ T cells were considered increased, as previously published, and the 97.5th percentile in the controls was the upper limit of normal for CD4+CXCR5+ T cells expressing CXCR3 and/or CCR6 and autoantibody intensity and number. RESULTS: We found that 27.7% of patients had increased percentages of CD4+CXCR5+PD1+ cTfh cells, and 42.5% had increased percentages of CD4+CXCR5+ cells expressing CXCR3 and/or CCR6. Patients had significantly more diverse IgG and IgA autoantibodies than controls, and 37.5% of patients had increased numbers of high-titer autoantibodies. Integrating measurements of cTfh cells, CD4+CXCR5+ T cells with CXCR3 and/or CCR6, and numbers of high-titer autoantibodies had 71.4% sensitivity (95% CI 58.5%-81.6%) and 85.0% specificity (95% CI 64.0%-94.8%) for patients with PIRD compared with controls. CONCLUSIONS: Integrating CD4+ T-cell phenotyping and total burden of autoantibodies can enhance detection of autoimmunity in PIRD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesAutoimmune DiseasesT Follicular Helper CellsHumansChildMaleFemaleAdolescentChild, PreschoolReceptors, CXCR3Receptors, CXCR5Receptors, CCR6InfantImmunoglobulin AProgrammed Cell Death 1 ReceptorImmunoglobulin G

Stichwörter der Autor:innen

AutoimmunityT follicular helper cellsautoantibodiesprimary immune regulatory disorders

Substanzen

AutoantibodiesReceptors, CXCR3CXCR3 protein, humanReceptors, CXCR5CXCR5 protein, humanReceptors, CCR6Immunoglobulin AProgrammed Cell Death 1 ReceptorCCR6 protein, humanImmunoglobulin G

Autor:innen und Institutionen

  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Mass.
  • Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Mass.
  • Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Mass; Northeastern University, Boston, Mass.
  • Standard BioTools, San Francisco, Calif.
  • Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Mass. Electronic address: Janet.Chou@childrens.harvard.edu.

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • NICHD NIH HHS
  • NIAID NIH HHS
  • NIH NIAID
  • NIDDK
  • Immune Deficiency Foundation
  • Thrasher Research Fund

Zitieren

APA

Harris, E. M., Chamseddine, S., Chu, A., Senkpeil, L., Nikiciuk, M., Bourdine, A., Magin, L., Al-Musa, A., Woods, B., Ozdogan, E., Saker, S., Hoytema van Konijnenburg, D. P., Yee, C. S. K., Nelson, R. W., Lee, P., Halyabar, O., Hale, R. C., Day-Lewis, M., Henderson, L. A., …, & Chou, J. (2025). T-cell and autoantibody profiling for primary immune regulatory disorders. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2025.06.007

Vancouver

Harris EM, Chamseddine S, Chu A, Senkpeil L, Nikiciuk M, Bourdine A, et al. T-cell and autoantibody profiling for primary immune regulatory disorders. Journal of Allergy and Clinical Immunology. 2025. doi:10.1016/j.jaci.2025.06.007

BibTeX
@article{Harris2025,
  author = {Harris, Emily M and Chamseddine, Sarah and Chu, Anne and Senkpeil, Leetah and Nikiciuk, Matthew and Bourdine, Aleksandra and Magin, Logan and Al-Musa, Amer and Woods, Brian and Ozdogan, Elif and Saker, Sarife and Hoytema van Konijnenburg, David P and Yee, Christina S K and Nelson, Ryan W and Lee, Pui and Halyabar, Olha and Hale, Rebecca C and Day-Lewis, Megan and Henderson, Lauren A and Nguyen, Alan A and Elkins, Megan and Ohsumi, Toshiro K and Gutierrez-Arcelus, Maria and Peyper, Janique M and Platt, Craig D and Grace, Rachael F and LaBere, Brenna and Chou, Janet},
  title = {T-cell and autoantibody profiling for primary immune regulatory disorders},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2025},
  doi = {10.1016/j.jaci.2025.06.007}
}
Kostenlos starten →